pathology microbiology and immunology Archives
H. pylori, lipid loss and stomach cancer
Jan. 17, 2022—H. pylori infection — a strong risk factor for stomach cancer — changes the composition of stomach lipids, which could offer new biomarkers for detecting premalignant changes, Vanderbilt researchers discovered.
Salmonella overcomes host resistance
Jan. 13, 2022—The invading pathogen Salmonella, a common cause of food poisoning, can change its metabolism to overcome host resistance to its colonization.
Study seeks to refine head and neck cancer treatment options
Jan. 13, 2022— by Bill Snyder Researchers at Case Western Reserve University and Vanderbilt University Medical Center are pioneering the use of computer-aided image analysis to improve the prognostication and treatment of head and neck cancer. Each year in the United States, approximately 16,000 patients are diagnosed with a form of head-and-neck cancer called oropharyngeal squamous cell...
Long-acting antibody combo developed at VUMC reduces COVID-19 risk and symptoms
Dec. 2, 2021— by Bill Snyder The global biopharmaceutical company AstraZeneca announced more good news about its long-acting combination of two monoclonal antibodies against COVID-19 that were discovered at Vanderbilt University Medical Center. In a prevention trial, one prophylactic, intramuscular injection of the antibody combination, called AZD7442, reduced the risk of symptoms occurring after exposure to the...
Seven from VUMC among most highly cited researchers
Nov. 18, 2021—Seven Vanderbilt faculty members have made this year’s list of scientists whose papers have been cited most frequently by other researchers.
CRISPR screen identifies new anti-inflammatory drug target
Nov. 11, 2021—A novel CRISPR screen developed by Vanderbilt researchers identified a promising new target for anti-inflammatory therapeutics.
VUMC researchers a step closer to broad ebolavirus protection
Oct. 28, 2021— by Bill Snyder A combination of two broadly acting monoclonal antibodies isolated by researchers at Vanderbilt University Medical Center protected non-human primates from ebolavirus disease, which causes severe and often-fatal hemorrhagic fever in humans. Their findings, published this week in the journal Cell, bring closer to development the first clinical therapy effective against all...
Diagnostic Laboratory Services set for relocation, expansion
Oct. 13, 2021—Vanderbilt's Diagnostic Laboratory Services are undergoing a major relocation and expansion project.
Amphibians offer clues to climate change resiliency
Oct. 7, 2021— by Bill Snyder Like the “canary in the coal mine,” the worldwide decline of amphibian populations, including frogs, toads and salamanders, during the past 50 years may be a harbinger of emerging infections and environmental changes that endanger humankind, as well. Just as important, some amphibian species have begun to recover from the global...
AstraZeneca seeks emergency approval for COVID-19 antibodies isolated at VUMC
Oct. 5, 2021—Biopharmaceutical company AstraZeneca has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration for a long-acting antibody combination originally developed at Vanderbilt University Medical Center to protect against COVID-19.
Molecular imaging of C. diff infection
Sep. 30, 2021—C. difficile — the leading cause of hospital-associated intestinal infections — induces a rapid influx of bile acids into the gut, which could provide a novel target for blocking infection.
“Ultra-potent” antibody against COVID-19 variants isolated at VUMC
Sep. 22, 2021—A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.